Rejuvenate Bio focuses on gene therapy as a novel approach to treating chronic, age-related diseases, which affect a significant portion of the American population. The company aims to develop ideal treatments that not only address compliance issues but also provide durable and well-tolerated solutions for patients suffering from these conditions. A key target in their research is FGF21, a protein that has demonstrated safety and efficacy in both large animal and human clinical trials. By activating critical biological pathways associated with various chronic diseases, FGF21 represents a promising avenue for therapeutic intervention.

The company employs liver-directed gene therapy, utilizing specialized capsids that deliver therapeutic proteins directly to a high percentage of target cells. This method minimizes the required dosage while ensuring sustained and durable efficacy, which is crucial for managing chronic diseases effectively. Rejuvenate Bio's collaboration with Phibro Animal Health for the development of a gene therapy targeting Mitral Valve Disease (MVD) exemplifies their strategy to create early revenue streams that can support further advancements in their human clinical programs. Overall, Rejuvenate Bio is positioned at the forefront of innovative treatments aimed at alleviating the burden of chronic diseases through advanced gene therapy techniques.

United States

Rejuvenate Bio is targeting the core drivers of chronic age-related diseases by unlocking the power of gene expression and epigenetic reprogramming to reverse pre-existing heart disease, metabolic disease, and kidney failure in humans.

Rejuvenate Bio

Company Details